Carvidon MR Tablets (Trimetazidine )

• Composition :
  Each tablet contains Trimetazidine 35mg Modified Release.
• Indications :
  Ischemic heart disease, angina pectoris and squeals of infarction.
• Pharmacodynamics :
  Trimetazidine inhibits beta-oxidation of fatty acids by blocking long-chain 3-ketoacyl-CoA thiolase, which enhances glucose oxidation. In an ischemic cell, energy obtained during glucose oxidation requires less oxygen consumption than in beta-oxidation process. Potentiation of glucose oxidation optimizes cellular energy processes, thereby maintaining proper energy metabolism during ischaemia.
• Dosage and administration :
  One tablet a day to be taken twice daily during meals.
• Contraindications :
  Trimetazidine is contraindicated in hypersensitivity to the active substance or to any of the excipients. Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, and other related movement disorders. Severe renal impairment (creatinine clearance < 30ml/min)
• Precautions and warnings :
  Not recommended for use in Parkinson's and moderate renal impairment.
• Use in pregnancy, lactation & pediatrics :
  Trimetazidine should not be taken during pregnancy unless clearly necessary. It should not be used during breast feeding. The safety and efficacy of trimetazidine in children aged below 18 years have not been established.
• Drug interactions :
  Occurrence of interactions with other medicinal products or foodstuffs has not been found. Trimetazidine can be used with heparin, calciparine, oral anticoagulants, medicinal products used in disturbances of lipid metabolism, salicylic acid, β-adrenolytic medicinal products, calcium channel blocking medicinal products, digitalis glycosides.
• Adverse reactions :
  Dizziness, headache, vomiting, diarrhea, dyspepsia, abdominal pain and nausea.
• Therapy Area :
  Anti-Anginals